Product Name: LRP4 (Extracellular)
Product Number: AB-NN286-1
Size: | 25 µg | | Price: | 89.00 |
| | | $US | |
Target Full Name: Low-density lipoprotein receptor-related protein 4
Target Alias: Corin; KIAA0816; LDLR; LDLR dan; LRP-4; LRP10; MEGF7; Multiple epidermal growth factor like domains 7
Product Type Specific: LRP4 pan-specific antibody
Antibody Code: NN286-1
Antibody Target Type: Pan-specific
Protein UniProt: O75096 Protein SigNET: O75096 Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG2A
Antibody Immunogen Source: Fusion protein amino acids 26- 350 (extracellular N-terminus) of mouse LTP4
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | ICC/Immunofluorescence
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: Detects a the extracellular domain of LRP4 ~215 kDa protein in cell and tissue lysates by Western blotting. Degradation product can be seen at ~150 kDa protein in cell and tissue lysates by Western blotting.
Antibody Species Reactivity: Mouse | Rat
Antibody Positive Control: 1 µg/ml of SMC-418 was sufficient for detection of LRP4 in 20 µg of rat brain lysate by colorimetric immunoblot
analysis using Goat anti-mouse IgG:HRP as the
secondary antibody.
Related Product 1: LRP4 (Cytoplasmic) pan-specific antibody (Cat. No.: AB-NN287-2)
Scientific Background: Potential cell surface endocytic receptor, which binds and internalizes extracellular ligands for degradation by lysosomes. It is involved in the negative regulation of the canonical Wnt signaling pathway, being able to antagonize the LRP6-mediated activation of this pathway.